国泰海通表示，AI技术正在推动制药领域的革新，英伟达与礼来合作建立AI+制药联合创新实验室，预 计未来五年投资最多10亿美元，以增强药物研发的核心生产力。TempusAI的业绩表明，AI在临床检测 与医疗数据商业化方面具有高度可复制性。当前，AI技术在制药行业的应用正迎来技术突破、资金活 跃和应用加速落地的共振阶段，推动行业向数据与算法驱动转型。 （文章来源：每日经济新闻） 恒生生物科技指数聚焦创新药"皇冠明珠"，具备龙头汇聚 × 稀缺期货活水 × 高弹性&高夏普三大优势。 投资者若希望便捷参与创新药核心龙头 ，可关注恒生生物科技ETF国泰（520933），实现一键布局。 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 责任编辑：宋雅芳 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，中邮证券发布研究报告，维持对"AI+医疗"行业"强于大市"的评级，认为该行业在政策与产业共 振下正迎来加速发展。华大智造、华大基因、晶泰控股、英矽智能、联影智能、鹰瞳科技等多家行业内 企业获关注。 近日，中邮证券发布研究报告，维持对"AI+医疗"行业"强于大市"的评级，认为该行业在政策与产业共 振下正迎来加速发展。华大智造、华大基因、晶泰控股、英矽智能、联影智能、鹰瞳科技等多家行业内 企业获关注。 研报指出，全球AI医疗市场预计将从2022年的137亿美元迅猛增长至2030年的1553亿美元。政策层面， 国家多部门联合推动"人工智能+制造"，重点鼓励AI在高端医疗装备等场景的应用，为行业注入强心 剂。同时，海外领先企业如TempusAI业绩高增、英伟达与礼来巨额投资共建AI实验室等动向，也强化 了全球产业高景气度的预期。 报告分析，AI技术已在制药、辅助诊断、影像手术及医疗服务等多个医疗细分领域步入成熟。在辅助 诊断方向，具备高质量数据与技 ...

Core Viewpoint - The Hong Kong stock market is experiencing a significant rally in the healthcare sector, particularly in AI healthcare stocks, with notable gains in companies like Ark Health and Yimaitong, driven by recent developments in AI and drug innovation [1][4]. Group 1: Market Performance - The Hong Kong healthcare sector has seen an 8-day consecutive rise, with AI healthcare stocks like Ark Health surging by 33% and Yimaitong increasing by over 10% [1]. - The Hong Kong Stock Connect Medical ETF (Huabao, 159137) reached a peak increase of 4.87% during trading, reflecting strong investor interest [1]. - The innovative drug sector within the Hong Kong Stock Connect also saw gains, with Rongchang Bio leading with over a 9% increase and Sanofi Biopharma rising by more than 7% [1]. Group 2: AI Healthcare Developments - Nvidia and Eli Lilly announced a joint investment of $1 billion to establish a lab in San Francisco focused on using AI to accelerate drug development [4]. - TempusAI reported FY25 revenue of approximately $1.27 billion, marking an 83% year-over-year increase, with a total contract value exceeding $1.1 billion [4]. - Zhejiang Qiang Brain Technology recently submitted an IPO application to the Hong Kong Stock Exchange, potentially becoming the first listed company in China's brain-computer interface sector [4]. Group 3: AI Integration in Healthcare - The penetration rate of AI in consumer healthcare is rapidly increasing, with Ant Group's AI assistant surpassing 30 million monthly active users and OpenAI's ChatGPT Health reaching over 40 million daily users globally [5]. - The healthcare sector is identified as a direct downstream application for medical information technology and AI, with expectations for significant productivity improvements [5]. - The exploration of business models in innovative drugs is highlighted as a core focus, with AI-driven drug development platforms forming strategic partnerships with pharmaceutical companies [5].

Group 1: Market Performance - The Hong Kong stock market's healthcare sector has seen a continuous rise for the eighth consecutive day, with AI healthcare stocks like Ark Health surging by 33% and Medical Pulse rising over 10% [1][8] - The Hong Kong Stock Connect Medical ETF (159137) reached a peak of 4.87% during trading, indicating strong investor interest in the healthcare innovation index, which includes sectors like CXO, AI healthcare, medical devices, and innovative drugs [1][8] - The Hong Kong Stock Connect innovative drug sector also experienced gains, with Rongchang Bio leading with over a 9% increase and 3SBio rising more than 7% [3][8] Group 2: AI and Pharmaceutical Developments - Nvidia and Eli Lilly announced a joint investment of $1 billion to establish a laboratory in San Francisco focused on using AI to accelerate drug development [5][11] - TempusAI reported FY25 revenues of approximately $1.27 billion, reflecting an 83% year-over-year growth, with total contract value exceeding $1.1 billion by the end of 2025 [5][11] - Tsinghua University announced the development of an AI-driven high-throughput drug virtual screening platform, DrugCLIP, which has been published in the journal "Science" [6][11] Group 3: Market Trends and Insights - The penetration rate of AI in healthcare is rapidly increasing, with significant user growth for platforms like Ant Group's AI assistant, which surpassed 30 million monthly active users [6][11] - Analysts suggest that the healthcare sector is a direct downstream of pharmaceutical information technology and AI applications, indicating potential productivity improvements [12] - The exploration of business models in AI and pharmaceuticals is becoming a core focus, with strategic collaborations between AI drug development platforms and pharmaceutical companies expected to catalyze stock performance [12]

在打破传统的审美边界后，AI已成为公募基金业绩的核心驱动力。 尽管估值、盈利、现金流仍是公募选股的核心指标，但以AI为代表的新物种持续火爆，以及低估值选股并不能保住基金 业绩的事实，也让许多基金公司、基金经理在审美逻辑上悄然变化，举牌、重仓的逻辑更重视动态变化与未来变现，而 非当前静态的业绩和估值，也是许多公募基金勇敢下注的原因。 公募重仓AI 今年以来，重仓AI在公募投资圈已不再是时髦的操作，更成为一种常识。Wind数据显示，截至9月14日，包含QDII在内 的基金业绩前20强产品，几乎清一色将核心仓位指向AI，当前业绩最佳的永赢科技智选年内收益已近1.9倍，业绩来自对 AI产业链的超配策略。基金经理没有重仓AI的后果也很严重，东方阿尔法招阳C基金年内收益率仍亏损约13%，业绩排名 全市场倒数第一，截至今年6月末，该基金的前十大股票无AI产业公司现身。 AI赛道股的火爆，也让许多公募老产品焕发新生。成立已经十余年的长盛城镇化主题基金今年收益约85%，排名已进入 全市场业绩前列。这只老基金在投资审美偏好估值与盈利，曾以水泥、房地产、白酒、工程机械等低估值龙头作为布局 核心，但业绩在市场中的存在感较弱，而在基金 ...

Investment Rating - The industry investment rating is "Positive" for the internet media sector, indicating an expectation of outperformance compared to the overall market [3]. Core Insights - The report highlights that the Q1 2025 performance of the A-share media sector, particularly in gaming, showed a significant year-on-year net profit growth of 38.6%. Companies like KeYing Network, Giant Network, and G-bits exceeded expectations, while Perfect World and Iceberg Network met high growth forecasts. The introduction of new products is expected to drive continued performance improvement in Q2 and the second half of the year [3]. - The report emphasizes the ongoing advancements in AI gaming, with several key startups entering the testing phase for native AI games. The film sector is noted for its cautious outlook on Q1 box office performance, but there is optimism regarding content companies' proactive IP management and animation film strategies [3]. - The report also mentions the resilience of advertising companies like Focus Media, anticipating improved bargaining power post-industry consolidation [3]. Summary by Sections Gaming Sector - Q1 2025 saw many companies in the gaming sector outperform expectations, with notable growth from KeYing Network, Giant Network, and G-bits. The overall gaming revenue is projected to grow by 9% in 2025 and 8% in 2026 [5]. - The introduction of AI in gaming is expected to mark a turning point in cost efficiency, with several AI games nearing launch [3]. Film and Content - The film sector's Q1 box office performance is expected to be disappointing, but companies are actively investing in IP operations and animation films, with significant growth seen in companies like Shanghai Film and Guomai Culture [3]. - The report indicates a 201% year-on-year growth in net profit for Shanghai Film, highlighting the potential in the animation film sector [5]. Advertising Sector - Focus Media is noted for its resilience, with a projected revenue growth of 10% in 2025 and 7% in 2026. The company is expected to enhance its bargaining power following industry consolidation [5]. AI and Cloud Computing - The report underscores the strong performance of several AI and cloud computing companies in the US, with Microsoft Azure and Meta exceeding expectations. The domestic market is also seeing advancements, particularly with Alibaba's Qwen3 model [3]. - The anticipated release of various AI products in Q2 is expected to further drive growth in this sector [3].